TABLE 2.
No UASs | UASs | p-value | |
Subjects | 104 | 59 | |
Female | 64 (61.5) | 40 (67.8) | 0.424 |
Age at onset years | 45.01±23.5 | 33.5±23.9 | 0.007 |
Age at diagnosis years | 64.0±15.0 | 59.4±17.7 | 0.201 |
Time from onset to diagnosis years | 13.0 (3.6–27) | 24 (7.7–40.6) | 0.020 |
Presence of asthma | 5 (4.8) | 7 (11.9) | 0.122 |
Idiopathic aetiology | 50 (48.1) | 31 (52.5) | 0.584 |
Post-infectious aetiology | 31 (29.8) | 7 (11.9) | 0.009 |
Eosinophils µL−1 | 200 (50–500) | 290 (158–488) | 0.002 |
IgE IU·mL−1 | n=61 42 (11–114) |
n=42 100 (13–305) |
0.066 |
IgG IU·mL−1 | n=79 1169 (1007–1350) |
n=53 1184 (962–1449) |
0.747 |
FEV1 % pred | 81±26 | 81±26 | 0.961 |
Chest CT Reiff score | n=86 7 (5–12) |
n=46 6 (5–10) |
0.632 |
Sinus CT Lund–Mackay score | n=38 0.5 (0–2) |
n=34 12 (8–13.0) |
<0.0001 |
Exacerbations per year n | 2 (1–4) | 3 (2–4) | 0.035 |
Occurrence of exacerbation in previous year | n=100 86 (86.0) |
n=58 56 (96.6) |
0.034 |
Data are presented as n, n (%), mean±sd or median (interquartile range), unless otherwise stated. FEV1: forced expiratory volume in 1 s; CT: computed tomography. p<0.05 was considered significant.